Neuralink’s implied valuation in secondary markets has climbed sharply to the $42–53 billion range as of early October 2026, driven by sustained investor demand for shares despite the last priced round—a $650 million Series E in June 2025 at roughly $9.7 billion post-money. Traders monitor tokenized perpetuals and private-market platforms where per-share quotes have recently traded near $150, reflecting optimism around expanding human trials (now exceeding 21 participants) and ongoing preclinical work, including a recent canine implant. With the October 31 resolution date approaching, near-term catalysts are limited to any disclosed secondary transactions or trial updates that could reset marks before month-end, though the company remains pre-revenue and without an IPO filing.